Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 408-414

  Hsueh, Po Ren ^a   Badal, Robert E ^b   Hawser, Stephen P ^c   Hoban, Daryl J ^b   Bouchillon, Samuel K ^b   Ni, Yuxing ^d   Paterson, David L ^e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Division of Microbiology   (United States)

^c International Health Management Associates Europe Sàrl   (Switzerland)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carbapenems; Enterobacteriaceae; Extended spectrum lactamase (ESBL); Fluoroquinolones; Intra abdominal infections; SMART

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOSURVEILLANCE; BROTH DILUTION; CHINA; CITROBACTER FREUNDII; COMMUNICABLE DISEASE; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; HONG KONG; HOSPITAL INFECTION; IN VITRO STUDY; INDIA; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MALAYSIA; MOLECULAR EPIDEMIOLOGY; NEW ZEALAND; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SINGAPORE; SOUTH KOREA; SPECIES COMPARISON; SPECIES DISTRIBUTION; TAIWAN; THAILAND; TREND STUDY;

ABDOMEN; ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PACIFIC ISLANDS;

EID: 77957662328     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.002     Document Type: Article

References (30)

1. Crandon J.L., Kuti J.L., Jones R.N., Nicolau D.P. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance. Ann Pharmacother 2009, 43:220-227.
2. Nijssen S., Florijn A., Bonten M.J., Schmitz F.J., Verhoef J., Fluit A.C. β-Lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004, 24:585-591.
3. Ko W.C., Hsueh P.R. Increasing extended-spectrum β-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the SMART study 2002-2006. J Infect 2009, 59:95-103.
4. Chow J.W., Satishchandran V., Snyder T.A., Harvey C.M., Friedland I.R., Dinubile M.J. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2005, 6:439-448.
5. Paterson D.L., Rossi F., Baquero F., Hsueh P.R., Woods G.L., Satishchandran V., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005, 55:965-973.
6. Rossi F., Baquero F., Hsueh P.R., Paterson D.L., Bochicchio G.V., Snyder T.A., et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006, 58:205-210.
7. Hsueh P.R., Snyder T.A., Dinubile M.J., Satischandran V., McCarroll K., Chow J.W., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2006, 28:238-243.
8. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D. Emergence of high levels of extended-spectrum β-lactamase-producing Gram-negative bacilli in Asia/Pacific: data from SMART 2007. Antimicrob Agents Chemother 2009, 53:3280-3284.
9. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
10. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2008-06-27 (version 1.2). [accessed 20 May 2010]. http://www.eucast.org/.
12. Clinical and Laboratory Standard Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M07-A7. Wayne, PA: CLSI; 2006.
13. Yagci D., Yoruk F., Azap A., Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009, 53:1287-1289.
14. Lautenbach E., Metlay J.P., Weiner M.G., Bilker W.B., Tolomeo P., Mao X., et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009, 30:18-24.
15. Apisarnthanarak A., Kiratisin P., Saifon P., Kitphati R., Dejsirilert S., Mundy L.M. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 2007, 35:606-612.
16. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
17. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009, 53:5046-5054.
18. Lautenbach E., Weiner M.G., Nachamkin I., Bilker W.B., Sheridan A., Fishman N.O. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27:893-900.
19. Tanimoto K., Tomita H., Fujimoto S., Okuzumi K., Ike Y. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother 2008, 52:3795-3800.
20. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J.C., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:133-164.
21. Solomkin J.S., Mazuski J.E., Baron E.J., Sawyer R.G., Nathens A.B., DiPiro J.T., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 37:997-1005.
22. Hsueh P.R., Hawkey P.M. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia. Int J Antimicrob Agents 2007, 30:129-133.
23. Chen W.Y., Jang T.N., Huang C.H., Hsueh P.R. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2006. J Microbiol Immunol Infect 2009, 42:317-323.
24. Labombardi V.J., Rojtman A., Tran K. Use of cefepime for the treatment of infections caused by extended spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:313-315.
25. Zanetti G., Bally F., Greub G., Garbino J., Kinge T., Lew D., et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003, 47:3442-3447.
26. Bhavnani S., Ambrose P., Craig W.A., Dudley M., Jones R. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006, 54:231-236.
27. Dalhoff A., Ambrose P.G., Mouton J.W. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009, 37:296-305.
28. Andes D., Craig W.A. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005, 11(Suppl 6):10-17.
29. Ambrose P.G., Bhavnani S.M., Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST Program. Antimicrob Agents Chemother 2003, 47:1643-1646.
30. Ambrose P.G. Monte-Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26:129-134.